

Target	Internalizing Aptamer	miRNA or antimiR mimics	Type of conjugate	Tumor models (cells)	Reference
Axl	GL21.T	Let-7g	“Two-blocks”	NSCLC (A549)	[46]
Axl	GL21.T	miR-212	“Two-blocks”	NSCLC (A549)	[49]
Axl	GL21.T	Let7g	“Three-blocks”	NSCLC (A549)	[46]
Axl	GL21.T	miR-16	“Three-blocks”	NSCLC (A549)	[46]
Axl	GL21.T	miR-34c	“Three-blocks”	NSCLC (Calu-1 A549)	[51]
Axl	GL21.T	miR-137	“Three-blocks”	NSCLC (A549 and patient-derived)	[52]
Axl	GL21.T	miR148b	“Three-blocks”	BC (MDAMB231 and 4175-TGL) and melanoma (MA-2 and MC-1)	[53]
KIT	Anti-KIT aptamer	miR-26a	“Two-blocks”	BC (MDA-MB-231)	[55]
Nucleolin	AS1411	Let-7d	“Two-blocks” (post-synthesis)	Gastric (MKN-45)	[56,57]
Axl	GL21.T	antimir-222 and miR-10b	“Two-blocks”	GBM (U87MG)	[59]
Axl and PDGFR β	GL21.T and Gint.4.T	miR-137 and antimiR10b	“Three-blocks”	GSC cells	[60]
EGFR	Anti-EGFR aptamer	antimiR21	three-way junction (3WJ)-based nanostructure	BC (MDA-MB-231)	[62]

Supplementary Table 1: Aptamer-based miRNA and antimiR conjugates. A summary of the aptamer-miRNA and aptamer-antimiR conjugates which are detailed in the review. The table includes information regarding the aptamer used, its recognized target, the miRNA or antimiR mimic conjugated to the aptamer, the type of conjugation according to the classification discussed, and the cellular models used for the validation.